4565 — Nxera Pharma Co Balance Sheet
0.000.00%
- ¥80bn
- ¥112bn
- ¥29bn
Annual balance sheet for Nxera Pharma Co, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 40,008 | 60,173 | 66,557 | 49,381 | 36,203 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,359 | 2,208 | 2,520 | 7,163 | 9,089 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 42,018 | 62,808 | 69,942 | 65,112 | 57,855 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3,824 | 3,817 | 3,791 | 7,900 | 7,468 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 76,465 | 96,985 | 99,417 | 157,198 | 151,498 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2,985 | 7,191 | 4,092 | 17,185 | 15,632 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 24,084 | 39,517 | 41,481 | 90,388 | 82,980 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 52,381 | 57,468 | 57,936 | 66,810 | 68,518 |
Total Liabilities & Shareholders' Equity | 76,465 | 96,985 | 99,417 | 157,198 | 151,498 |
Total Common Shares Outstanding |